3 Stock Stars Yielding Around 5% In 2015: GlaxoSmithKline plc, Legal & General Group Plc & Old Mutual plc

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), Legal & General Group Plc (LON: LGEN) and Old Mutual plc (LON: OML) should attract savvy dividend seekers.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three blue-chip winners set to deliver stunning returns in 2015.

GlaxoSmithKline

The effect of revenues-sapping patent losses has weighed heavily on GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) bottom line in recent years, and the firm has failed to punch two consecutive years of growth for what seems an age now. And City analysts expect this trend to continue during the medium term at least, with a 17% earnings slide pencilled in for this year.

Despite these travails, the pharma giant’s ability to throw up plenty of cash has enabled it to continue raising the full-year dividend during this time — GlaxoSmithKline has lifted the payment at a compound annual growth rate of 6.3% during the past five years alone.

And the number crunchers expect the dividends to continue rolling higher as a result, and GlaxoSmithKline is anticipated to raise the payout 3% in 2014, to 80.1p per share, and a further 1% next year to 81p. Consequently the Brentford firm boasts a chunky yield of 5.4% for this year — comfortably above the 3.3% FTSE 100 average — and which advances to 5.5% for 2015.

Earnings are expected to flip 1% higher next year as the company’s promising drug pipeline begins to deliver the next generation of sales-boosting drugs, a promising omen for future payout growth. And with GlaxoSmithKline embarking on a new £1bn cost-saving initiative, I believe that the firm’s already-attractive dividend outlook should improve considerably in coming years.

Legal & General Group

Backed up by an aggressive acquisition policy and emphasis on developing its brand in emerging markets, Legal & General (LSE: LGEN) (NASDAQOTH: LGGNY.US) has seen growth spurt skywards during the past couple years. When combined with the firm’s terrific cash-generative qualities, boosted by surging business inflows, dividends are expected to keep marching higher though to the end of 2015.

Indeed, an 11% earnings advance in 2014 is anticipated to push the full-year dividend 19% higher this year to 11.1p per share. And an additional 9% increase in 2015 will drive the payout 13% northwards to 12.5p, according to City analysts. As a result Legal & General’s chunky yield of 4.5% for this year shoots to a wallet-busting 5.1% for 2015.

Legal & General has seen the value of its international assets treble during the past four years, and I believe that a backcloth of rising affluence levels and low product penetration in key growth markets should keep the sales column ticking higher. Meanwhile a diversified product base spanning the insurance, savings and investment spheres should guard against earnings weakness and keep dividends flowing.

Old Mutual

Life insurance giant Old Mutual (LSE: OML) has maintained an ultra-progressive dividend policy in recent years despite the effect of wavering earnings growth, a phenomenon which the abacus bashers expect to continue during the next 12 months at least.

A 9% advance in the full-year payout is currently pencilled in for 2014, to 8.75p per share, despite an anticipated 10% earnings drop. And with the bottom line predicted to expand 16% in 2015, Old Mutual will push the dividend 13% higher to 9.9p, according to current forecasts.

Accordingly, yields at the business rise from 4.3% this year to a far more appetising 4.9% for 2015.

The firm’s huge reliance on the South African market has seen group sales slow more recently owing to weak consumer trends there. Still, I believe that once current cyclical woes in its critical African markets abate — boosted by improvements in its product distribution infrastructure — Old Mutual should see earnings and dividends continue to surge beyond next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

With a P/E ratio of 9, is the Aviva share price a bargain?

Christopher Ruane looks at the Aviva share price and considers some strengths and weaknesses of the FTSE 100 insurance business.

Read more »

Surprised Black girl holding teddy bear toy on Christmas
US Stock

Is it too late to buy growth stock Shopify after its 25% pop?

Up more than 40% this year, Shopify is on fire at the moment. Here, Edward Sheldon explains how he’d play…

Read more »

Investing Articles

Investors should consider buying this energy AIM stock, up 50% in the past year

AIM stock Afentra has seen a stellar price rise in 12 months to November. I believe there may be room…

Read more »

Investing Articles

2 ISA shares to consider for a large passive income!

Looking for dividend shares to buy in a Stocks and Shares ISA or Lifetime ISA? Royston Wild reveals two of…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

A Bitcoin investment that can be held inside a Stocks and Shares ISA or SIPP

UK investors can’t buy Bitcoin ETFs for their investment accounts or SIPPs due to FCA regulation. This stock could be…

Read more »

Entrepreneur on the phone.
Investing Articles

As the Vodafone share price slides 6% on lacklustre H1 results, what does the future hold?

After posting moderate results this morning, Vodafone saw its share price sink further, erasing this year's gains. Our writer looks…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing For Beginners

If I’d invested £5k in a FTSE tracker fund after the pandemic crash, here’s what I’d have now

Jon Smith explains the extent of his potential gains if he'd invested in a FTSE tracker fund during the Covid…

Read more »

Investing Articles

2 top shares I’ve bought for my Stocks and Shares ISA in November

This writer reveals a pair of fast-growing businesses that he's recently added to his Stocks and Shares ISA for the…

Read more »